![]() |
市場調査レポート
商品コード
1462285
BRII-835+BRII-179の市場規模、予測、新薬の考察(2032年)BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032 |
||||||
カスタマイズ可能
適宜更新あり
|
BRII-835+BRII-179の市場規模、予測、新薬の考察(2032年) |
出版日: 2024年04月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
BRII-836(VIR-2218)は、試験中のHBVを標的とする皮下投与のsiRNAであり、効果的な免疫反応を刺激し、HBVとHDVに対して直接的な抗ウイルス活性を有します。このsiRNAは、安定性を高め、オフターゲット活性を最小化するESC+(Enhanced Stabilization Chemistry Plus)技術を搭載した臨床初のsiRNAであり、潜在的に治療指数の向上をもたらす可能性があります。
また、BRII-179(VBI-2601)は、Pre-S1、Pre-S2、SのHBV表面抗原を発現し、B細胞とT細胞免疫の増強を誘導するように設計された、新しい組換えタンパク質ベースのHBV免疫療法候補薬です。Brii Bioは2018年12月にVBIワクチンからBRII-179(VBI-2601)のライセンスを受け、中国本土、中国香港、マカオ、台湾のライセンス地域におけるBRII-179(VBI-2601)の商業権を得ました。
いずれの薬剤もHBV患者における機序が証明されており、併用することで機能的治癒が期待できる可能性があります。この薬剤は、siRNA遺伝子サイレンシングにより免疫抑制性ウイルス抗原を除去し、免疫療法ワクチンにより宿主HBV特異的免疫を刺激し回復させるという、二重の作用機序を包含しています。
当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)と中国市場におけるB型慢性肝炎向けBRII-835+BRII-179について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about BRII-835 + BRII-179 for chronic hepatitis B in the seven major markets and China. A detailed picture of the BRII-835 + BRII-179 for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019 -2032 is provided in this report along with a detailed description of the BRII-835 + BRII-179 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BRII-835 + BRII-179 market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.
BRII-836 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that can stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index.
Also, BRII-179 (VBI-2601) is a novel recombinant, protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens and is designed to induce enhanced B-cell and T-cell immunity. Brii Bio licensed BRII-179 (VBI-2601) from VBI Vaccines in December 2018, providing Brii Bio with commercial rights to BRII-179 (VBI-2601) in the licensed territories of Mainland China, China Hong Kong, Macau, and Taiwan.
Both agents have demonstrated proof of mechanism in HBV patients; a combination might be a potential functional cure. It encompasses dual mechanisms of action, removing immunosuppressive viral antigens by siRNA gene silencing followed by stimulating and restoring the host HBV-specific immunity with an immunotherapeutic vaccine.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
BRII-835 + BRII-179 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of BRII-835 + BRII-179 for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of BRII-835 + BRII-179 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.